Health TrialsbyHealthPanel

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)

Participants needed: 54
Trial details
Phase: Phase 1Biological sex: AllType: InterventionalSponsor: Nuvectis Pharma, Inc.Updated: Aug 25, 2026Locations: 1
Eligibility criteria

18 years old or older [+4]

Known single or compound ALK domain mutations that cause resistance to lorlatini... [+1]

Read more
Status: Recruiting

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)

Participants needed: 18
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Nuvectis Pharma, Inc.Updated: Jul 9, 2026Locations: 6
Eligibility criteria

Provide written informed consent. [+4]

Subject's cancer has a known oncogenic driver alteration other than EGFR. [+3]

Read more